Repurposing Approved Drugs to Modulate DNA Repair in CRISPR Editing

Study Background and Research Question

DNA double-strand breaks (DSBs) are critical lesions that threaten genomic integrity. While DSBs can arise spontaneously from metabolic byproducts or be induced by exogenous sources such as ionizing radiation and chemotherapeutic agents, genome editing technologies like CRISPR-Cas9 exploit targeted DSBs to achieve precise genetic modifications (reference). The outcome of DSB repair is governed by three main pathways: non-homologous end joining (NHEJ), microhomology-mediated end joining (MMEJ), and homology-directed repair (HDR). Each pathway results in distinct genomic alterations, with NHEJ and MMEJ typically generating small indels and HDR allowing template-driven precise edits. However, the cell's preference for a particular repair pathway remains a bottleneck for predictable genome editing, gene therapy, and synthetic lethality approaches. This study sought to systematically identify clinically approved drugs that shift the balance among DSB repair pathways, enhancing the precision and predictability of CRISPR-mediated genome engineering.

Key Innovation from the Reference Study

The central innovation of this study lies in its comprehensive drug repurposing screen: over 7,000 FDA-approved drugs and investigational agents were evaluated for their ability to modulate DSB repair pathway choice in human induced pluripotent stem cells (hiPSCs) subjected to CRISPR-mediated editing (reference). By quantifying DNA repair outcomes at the sequence level, the authors could classify compounds as enhancers or inhibitors of NHEJ, MMEJ, or HDR. Notably, the study not only identified molecules that bias repair towards precise HDR, but also those capable of inducing synthetic lethality when combined with pathway-specific inhibition—an approach with significant implications for cancer therapy and precision medicine. Furthermore, the work uncovered unanticipated roles for proteins like ESR2 and AOX1 in regulating DSB repair, providing new avenues for therapeutic intervention.

Methods and Experimental Design Insights

The researchers employed a robust workflow leveraging hiPSCs engineered with a doxycycline-inducible Cas9 system (iCRISPR). Upon induction, Cas9 and a guide RNA targeted the FRMD7 locus, creating a site-specific DSB. Each drug candidate was added during the editing window, and after recovery, cell viability and editing outcomes were assessed. Cell survival was measured by a resazurin fluorescence assay, while DNA from surviving cells was extracted, PCR-amplified, and subjected to high-throughput Illumina sequencing to analyze mutational spectra (reference). This allowed precise classification of repair events (e.g., insertions, deletions, HDR, and pathway-specific signatures). Silencing experiments targeting ESR2 and AOX1 further dissected the contributions of these proteins to repair outcomes. The screen design enabled high-throughput, quantitative evaluation of both direct and synergistic effects of small molecules on DSB repair choice.

Protocol Parameters

• assay | CRISPR editing in hiPSCs | 409B2 hiPSC line, doxycycline-inducible Cas9 | Enables controlled DSB induction at defined loci | literature-backed (reference)
• assay | Drug library screening | >7,000 compounds, single replicate per condition | Maximizes chemical diversity; enables identification of rare modulators | literature-backed (reference)
• assay | Resazurin viability assay | endpoint fluorescence | Quantifies cytotoxicity and synthetic lethality | literature-backed (reference)
• assay | DNA repair outcome quantification | Illumina sequencing, pathway classification | High-resolution mapping of indels, HDR, and large deletions | literature-backed (reference)
• assay | Application of ryanodine receptor antagonist (e.g., Dantrolene sodium salt) | 5.9 ± 0.3 nM (IC50 for RyR2) | Potential for calcium signaling modulation in genome editing contexts | workflow_recommendation (product_spec)

Core Findings and Why They Matter

This study yielded several impactful discoveries. Most importantly, it cataloged compounds that can bias DSB repair pathway usage—some promoting precise HDR (increasing the efficiency of template-driven editing), others inhibiting error-prone NHEJ or MMEJ. For instance, when NHEJ was pharmacologically inhibited and ESR2 silenced, HDR rates increased synergistically by a mean of 4.6-fold, a significant enhancement for applications requiring high-fidelity genome correction (reference). The screen also identified drugs that, when combined with pathway-specific inhibitors, induce synthetic lethality—killing cells with particular repair deficiencies, a strategy highly relevant for targeting cancers with defined DNA repair mutations. These findings open new possibilities for programmable editing, disease modeling, and precision therapeutics, where shifting DSB repair dynamics can greatly improve experimental and clinical outcomes.

Comparison with Existing Internal Articles

Several internal resources provide complementary perspectives on related research tools and mechanisms. For example, the article "Dantrolene Sodium Salt: Unveiling New Frontiers in RyR Signaling" discusses the use of Dantrolene sodium salt—a potent ryanodine receptor antagonist—in dissecting calcium signaling and its impact on DNA repair pathway regulation. While the reference study did not directly test Dantrolene, mechanistic overlap exists: calcium homeostasis modulates repair pathway activity, and ryanodine receptor antagonists have been used to influence intracellular calcium release in genome editing and synthetic lethality workflows (internal_article). Another internal article, "Targeting Ryanodine Receptor Signaling for Precision Modulation of DNA Repair", synthesizes current evidence linking ryanodine receptor inhibition with programmable genome editing outcomes. These resources collectively highlight the translational potential of integrating small-molecule modulators—such as Dantrolene sodium salt—in DNA repair and gene editing research, as supported by the large-scale drug screening approach of the primary study.

Limitations and Transferability

Although this study represents the most expansive drug repurposing screen for DSB repair pathway modulation to date, several limitations warrant consideration. The single-replicate design for each drug condition, while enabling scale, may miss subtle or context-dependent effects. Cell line specificity (hiPSCs) limits direct translation to primary cells or in vivo systems; repair pathway preferences and drug responses can differ across cell types and physiological contexts. Furthermore, while the screen identified candidate modulators, detailed mechanistic studies are required to confirm direct targets, off-target effects, and long-term genomic stability. Transferability to clinical or therapeutic settings will require validation in disease-relevant models, including those for neurodegenerative disease, ischemia, hypoxia, and cancer. Finally, not all compounds identified are equally suited for all research applications—further workflow-specific optimization is recommended (reference).

Research Support Resources

For researchers seeking to experimentally modulate intracellular calcium signaling and ryanodine receptor pathways in parallel to DNA repair studies, Dantrolene, sodium salt (SKU B6329) from APExBIO is a well-characterized ryanodine receptor antagonist (IC₅₀ = 5.9 ± 0.3 nM for RyR2; see product_spec). Its high purity and documented calmodulin-dependent inhibition profile make it suitable for workflows involving calcium signaling modulation, synthetic lethality, and genome editing research. Consult product specifications and relevant workflow recommendations for optimized use in your specific experimental context.